Business
GMT: Net loss narrowed and revenue rose, but continued funding and market risks persist
GMT: Net loss narrowed and revenue rose, but continued funding and market risks persist
About this update from Genomtec Sa
Revenue and net loss both improved year-over-year, with ongoing R&D and reliance on grants and new share issues. Geopolitical risks and market volatility remain significant, while new capital increases and incentive programs are planned.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.